Cargando…

Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial

Background In patients with nonvalvular atrial fibrillation (AF), apixaban is given in doses of 5 or 2.5 mg twice daily, according to clinical characteristics. The usual on-treatment range of apixaban drug levels, as determined by apixaban-calibrated anti-factor Xa (anti-Xa) activity, has previousl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhagirath, Vinai C., Eikelboom, John W., Hirsh, Jack, Coppens, Michiel, Ginsberg, Jeffrey, Vanassche, Thomas, Yuan, Fei, Chan, Noel, Yusuf, Salim, Connolly, Stuart J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2017
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524853/ https://www.ncbi.nlm.nih.gov/pubmed/31249919 http://dx.doi.org/10.1055/s-0037-1613679

Ejemplares similares

Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES
por: Benz, Alexander P., et al.
Publicado: (2021)

Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study
por: de Vries, Tim A.C., et al.
Publicado: (2022)

Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?
por: Shyamkumar, Krishnan, et al.
Publicado: (2021)

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
por: Margetić, Sandra, et al.
Publicado: (2019)

Averroes : las ambiciones de un intelectual musulmán /
por: Urvoy, Dominique
Publicado: (1998)

Al encuentro de Averroes
Publicado: (1993)

The Neurosciences in Averroes’ “Principles of Medicine”
por: Delgado, Fernando
Publicado: (2012)

Averroes y el averroísmo : ensayo histórico /
por: Renan, Ernest, 1823-1892

Ibn Rushd (Averroës): Prince of Science
por: Tbakhi, Abdelghani, et al.
Publicado: (2008)

Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism
por: Chan, Noel C, et al.
Publicado: (2015)

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
por: Martin, Andrew, et al.
Publicado: (2012)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
por: Mezue, Kenechukwu, et al.
Publicado: (2017)

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation
por: Spinthakis, Nikolaos, et al.
Publicado: (2019)

Prevention of Venous Thromboembolism in 2020 and Beyond
por: Nicholson, Matthew, et al.
Publicado: (2020)

Averroës' Middle commentary on Aristotle's De anima : a critical edition of the Arabic text /
por: Averroës, 1126-1198
Publicado: (2002)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
por: Ioannou, Adam, et al.
Publicado: (2017)

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
por: Kirchhof, Paulus, et al.
Publicado: (2018)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

Averroes' Physics: A Turning Point in Medieval Natural Philosophy
por: Glasner, Ruth
Publicado: (2009)

Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
por: Zeymer, Uwe, et al.
Publicado: (2020)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

La concepción de la filosofía en Averroes : análisis crítico del Tahafut al-thahafut /
por: Maiza Ozcoidi, Idoia
Publicado: (2001)

Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort
por: Candeloro, Matteo, et al.
Publicado: (2022)

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2020)

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
por: Gill, Dipender, et al.
Publicado: (2020)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Spontaneous Spinal Epidural Hematoma in a Patient on Apixaban for Nonvalvular Atrial Fibrillation
por: El Alayli, Ahmad, et al.
Publicado: (2020)

Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation
por: Seeger, Julia, et al.
Publicado: (2020)

The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
por: Lawrence, Matthew J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_td53tjug606bskpmdhbkp72kjd